Suzuken : Acquires Shares of medimo, Inc.

February 12, 2026

Press Release SUZUKEN CO., LTD.

Shigeru Asano, President and CEO (Stock Code: 9987)

Securities Traded: Prime Market of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters Tel.: +81-52-961-2331

Suzuken Acquires Shares of medimo, Inc.

SUZUKEN CO., LTD. (headquarters: Nagoya City, Aichi; President and CEO: Shigeru Asano; hereinafter “the Company”) hereby announces that it has acquired all shares of medimo, Inc. (headquarters: Minato-ku, Tokyo; Co-CEOs: Yo Nakahara and Shaoang Ma; hereinafter “Medimo”) and, as of today, has made it a wholly owned subsidiary as outlined below.

1. Objective and Background of the Subsidiary Acquisition

   At the Suzuken Group (hereinafter, “the Group”), based on our vision of creating new value to solve social issues through the integration of digital and real-world solutions, we are committed to building a secure and reliable healthcare platform. To realize this, we actively collaborate with various companies in the digital domain and work to generate new added value by strategically combining their respective capabilities.

   Medimo is a health-tech startup founded in April 2022 with the mission of “Ensuring sustainable healthcare through frontier technology.” To address the structural issue of a growing shortage of healthcare professionals, the company provides “medimo,” a SaaS platform for medical documentation that leverages generative AI as its core technology to enable voice-based input and automated summarization.

   Since the platform’s launch in April 2024, it has been implemented at more than 1,000 medical institutions nationwide. As it pursues medium- to long-term growth, Medimo aims to become an essential infrastructure that supports sustainable healthcare in Japan.

   Japan’s rapidly declining birthrate and aging population are driving up healthcare demand, while securing healthcare professionals is becoming increasingly difficult. As a result, the sustainability of the healthcare delivery system is under significant strain. Against these structural challenges, overtime-work regulations for physicians took effect in April 2024, further heightening the need for fundamental productivity improvements in healthcare settings to maintain both the quality and volume of care with limited human resources.

   In this environment, generative AI is spreading rapidly across society, mirroring the rise of the Internet and social networking services (SNS). Its adoption is also beginning to expand steadily across the healthcare and nursing care sectors.

   To remain competitive amid a tougher market environment and quickly respond to external changes surrounding us, the Group believes it is essential to strategically internalize generative AI capabilities and establish an organizational structure that enables rapid, proactive decision-making and execution.

   By bringing together the Suzuken Group’s traditional asset of a nationwide customer base of approximately 160,000 medical institutions and Medimo’s technological expertise, we will develop and roll out new generative-

   AI-based solutions to clinical settings throughout Japan, supporting sustainable healthcare delivery by helping address the shortage of healthcare professionals.

   In addition to accelerating broader adoption of the medical-documentation SaaS platform “medimo,” we will deploy generative AI across a wide range of functions within the Group. This will include enhancing the capabilities of our in-house solutions and systems, such as COLLABO Portal and Medical Care Station (MCS), thereby improving operational efficiency and productivity and further accelerating the commercialization and monetization of our digital businesses.

   As we prepare to launch our next medium-term management plan this April, we will continue to work with diverse partners to address social challenges. We will further accelerate initiatives that closely integrate generative AI with real-world infrastructure, build a secure and reliable healthcare platform, and advance toward realizing a health creation enterprise.

2. Overview of the Share Acquisition

   • The Company will acquire 100% of the issued and outstanding shares from existing shareholders.

   • The acquisition price and other terms will not be disclosed. However, the valuation reflects our high regard for Medimo’s expertise in the medical domain, advanced generative AI capabilities, and the rapid increase in the number of facilities implementing “medimo,” and therefore all shareholders have agreed to the terms. (To ensure fairness and appropriateness, the valuation and terms were determined with reference to the results of various due diligence reviews conducted by independent third-party organizations.)

3. Schedule

Share acquisition date: Thursday, February 12, 2026

• About medimo, Inc.

“medimo,” SaaS platform for medical documentation

By analyzing conversations during consultations, generative AI automatically generates highly accurate draft medical records.

Speech recognition tailored to medical terminology streamlines workflows, thereby supporting work-style reform and improving operational efficiency at the frontline of healthcare.

Corporate Communication Department, Suzuken Co., Ltd.

8 Higashikataha-machi, Higashi-ku, Nagoya City, Aichi 461-8701, Japan

Tel: 052-950-6307 Fax: 052-961-4071

https://www.suzuken.co.jp/en/